AI-powered Pathology to Transform NASH Clinical Trials​



AI-based NASH Scoring

PathAI has developed an AI-based measurement of NASH (AIM-NASH) tool that provides Clinical Research Network (CRN) NAFLD Activity Score (NAS) component grades and fibrosis stages with pathologist review, enabling accurate and efficient patient selection and endpoint analysis. 

Transforming NASH Clinical Trials

PathAI is dedicated to partnering with drug developers to get effective therapies to patients. Watch this video to learn how AI-powered pathology can support NASH trial success.

Applications & Case Studies​

NASH drug developers are utilizing AIM-NASH to de-risk their clinical trials​

Reduce impact of inter-observer variability

Concordance between AIM-NASH ordinal scores and manual consensus scores is greater than mean inter-pathologist concordance across all NASH CRN scoring components​

View Abstract



Meet clinical trial endpoints

Significantly greater number of primary endpoint responders is detected in treated vs. placebo arms by AIM-NASH but not manual scoring in Ph2 study of Pegbelfermin (PGBF)

View Poster


Measure drug activity and identify optimal dosage​

Significantly greater number of primary endpoint responders is detected in treated vs. placebo arms by AIM-NASH but not manual AIM-NASH detected dose-dependent treatment response in Ph2 study, in addition a statistically significant difference in proportion of patients achieving endpoints

View Poster


Questions? Contact us to explore opportunities to accelerate your NASH Clinical Program